猪伪狂疫苗

Search documents
永顺生物2025年半年报:净利润增长27% 创新驱动高质量发展
Quan Jing Wang· 2025-08-27 07:10
Core Insights - Yongshun Biological (stock code: 839729) reported a revenue of 122 million yuan for the first half of 2025, representing a year-on-year increase of 2.14% [1] - The net profit attributable to shareholders reached 19.72 million yuan, up 26.95% year-on-year, with a 50.72% increase when excluding the impact of share-based payments, indicating strong growth momentum [1] Business Performance - The core business of pig vaccines showed a significant recovery, with sales of live pig vaccines increasing by 13.95% year-on-year, driven by rising pig prices and increased enthusiasm among small and medium-sized farmers [1] - The revenue from the pig circovirus vaccine increased by 2.84 million yuan, becoming a new growth point for performance [1] Research and Development - The company increased its R&D investment to 10.25 million yuan, accounting for 8.42% of revenue, and successfully obtained new veterinary drug certificates and production licenses for several projects [1] - The company received clinical approval and invention patent authorization for multiple projects, laying a solid foundation for future development [1] Cost Management - Through continuous optimization of production processes, the unit costs of the main products, including the pig pseudorabies and avian influenza vaccines, decreased by approximately 11% and 9% respectively, significantly enhancing product competitiveness [1] - The company improved operational efficiency through supply chain optimization and refined management [1] Marketing Strategy - The company adheres to a "channel sinking, marketing terminal" strategy, resulting in a 22.60% year-on-year increase in domestic distributor revenue [2] - Significant success in overseas market expansion, particularly in Vietnam and Egypt, where revenue reached 13.03 million yuan, a substantial year-on-year growth of 88.61% [2] Future Outlook - Yongshun Biological will continue to pursue an innovation-driven development strategy, focusing on market demand, optimizing product structure, and enhancing product quality and service levels to consolidate and expand market advantages [2]